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Abstract Immune and inflammatory pathways have a
central role in the pathogenesis of non-alcoholic fatty liver
disease (NAFLD). Both the innate and adaptive immune
systems contribute to the development of NAFLD. Patho-
gen-associated molecular patterns and danger-associated
molecular patterns are known to activate a variety of pat-
tern-recognition receptors that result in inflammation. The
key features of the immune system and inflammatory
pathways in the development of NAFLD are discussed in
this review.
Keywords NAFLD  NASH  Inflammation 
PAMPs  DAMPs  Immunity
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most
common liver disease worldwide, affecting around one
third of the Western world with an incidence that continues
to grow even in other parts of the world [1, 2]. NAFLD
includes a variety of histopathological findings ranging
from simple steatosis with no inflammation to steatosis
with varying degrees of inflammation (steatohepatitis,
NASH) to cirrhosis [1]. It is thought that around 10–20 %
of patients with NAFLD have NASH [3]. Patients with
NASH have the potential to develop fibrosis and cirrhosis
leading to portal hypertension, liver decompensation, and
hepatocellular carcinoma [4].
The liver is composed of a diverse array of cell types,
most of which have the potential to be involved in
inflammation. Hepatocytes make up around 60–80 % of all
liver cells, and they are responsible for the metabolic,
biosynthetic, biliary secretion, and detoxification roles of
the liver. The liver is also enriched in various immune
cells. The resident innate immune cells in the liver are
comprised of Kupffer cells (KCs), the resident macro-
phages, and natural killer (NK) cells. Upon liver injury,
other innate immune cells, including neutrophils, leuko-
cytes, monocytes, and inflammatory macrophages, are
rapidly recruited to the liver. The adaptive immune cells
consist primarily of natural killer T (NKT) cells, B cells,
and T cells. Other cell types that may contribute to
inflammation and fibrosis are the sinusoidal endothelial
cells (SECs) and hepatic stellate cells (HSCs).
The cells in the liver contribute to the inflammation that
results in the development and progression of steatohepa-
titis, which is secondary to the immune response of the
liver to danger signals, likely from a combination of
exogenous and endogenous danger signals, which include
injured self-molecules, i.e., DNA and RNA. There are
multiple ‘‘hits’’ needed for NASH to develop and progress.
In addition to metabolic factors, innate immune alterations,
including inflammation caused by free fatty acids (FFA),
bacterial lipopolysaccharide (LPS), chemokines, cytokines,
and adipokines, all contribute [3].
Contribution of immune cells
Innate immune cells, consisting of KCs, neutrophils, den-
dritic cells (DCs), and NK cells, all play a role in the
pathogenesis of NASH. In the setting of acute or chronic
liver disease, KCs are activated by both pathogen-
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associated molecular patterns (PAMPs) and damage-asso-
ciated molecular patterns (DAMPs). This activation results
in the release of proinflammatory cytokines, such as tumor-
necrosis factor a (TNFa), interleukin-6 (IL-6), and inter-
leukin-1b (IL-1b), which lead to T cell activation and
induction of apoptosis and HSCs [5]. There are two types
of macrophages, M1 or ‘‘classically activated’’ macro-
phages, which play an important role in humoral immunity
and response to pathogens, and M2 or ‘‘alternatively acti-
vated’’ macrophages, which have anti-inflammatory prop-
erties. There is an increase in M1 relative to M2
macrophages in adipose tissue and in the liver in response
to high-fat diet (HFD) feeding and obesity [6–8]. The
imbalance between M1 and M2 macrophages may have an
important role in the pathogenesis of NASH. Depletion of
KCs attenuates methionine-choline-deficient (MCD) and
HFD-induced steatohepatitis [9, 10].
Activated neutrophils release proinflammatory cyto-
kines and myeloperoxidase, resulting in oxidative damage
to hepatocytes [11, 12]. Furthermore, an increase in the
ratio of neutrophils to lymphocytes can increase the like-
lihood of NASH progression [13]. DCs also appear to play
an important role in NASH, as recent reports have shown
that DC depletion results in worsening NASH severity,
suggesting a regulator role of DCs in NASH [14].
NK cells are an important component of the immune
system and play a role in linking the innate and adaptive
immune responses [15]. NK cells are abundant in the liver,
and in disease they have a role in the development of liver
injury and fibrosis. It is thought that NK cells could play a
role in the development of NAFLD/NASH. NK cell-acti-
vating ligands are increased in human NASH patients and
in mice following an MCD diet [16]. Obese patients have
both a decrease in circulating levels and impaired cytotoxic
function of NK cells as compared to lean controls [17].
Similar impairment in cytotoxic activity was determined to
be present in rats with HFD-induced obesity [18]. NK cells
may have an anti-fibrotic effect in the liver [19], and the
reduction in their levels and activity may contribute to the
increased susceptibility of obese patients to develop
cirrhosis.
Natural killer T (NKT) cells are a subset of lymphocytes
that express NK cell markers, such as CD161 and CD94, as
well as a T cell receptor. NKT cells exhibit features of both
innate and adaptive immune cells and act as a bridging
system between innate and adaptive immunity [20]. NKT
cells are enriched within the liver and regulate the immune
response by secreting both TH1 and TH2 cytokines after
stimulation [21]. Biopsies in patients with NAFLD showed
that NKT cell population was decreased when there was
moderate to severe steatosis [22]. Both obese leptin-defi-
cient ob/ob mice and HFD-induced obesity showed
reduced liver NKT cells [23, 24]. Upregulation of hepatic
NKT cells results in improvement of HFD-induced hepatic
steatosis [25]. Depletion of NKT cells leads to chronic
inflammatory conditions that contribute to hepatic steatosis
[23]. On the other hand, there is an increase of NKT cells in
MCD diet-induced steatohepatitis and in cirrhotic livers
[26]. NKT cells appear to drive production of osteopontin
and of hedgehog ligands leading to fibrogenesis, which
may explain the increase in NKT cells in the MCD diet
model and in cirrhotic livers [27].
Regulatory T cells (Tregs) are a subset of T cells that are
either naturally occurring or inducible. An important role
of the CD25? subset of Tregs is their suppression of CD4
and CD8 T cells and thus in a decrease in inflammation.
Mouse models have displayed that depleting CD25? Tregs
results in precipitation of autoimmune disease. In the liver,
it has been reported that there are increased Tregs in tumor
tissue in HCC patients and in patients with either chronic
HBV or HCV infection [28–30], suggesting that Tregs have
a role in either suppressing or maintaining tumor cells or
viral infection. In NASH livers, there are increased num-
bers of Tregs [31, 32]. Mice fed a HFD showed a gradual
decrease of Tregs over time, which may be a key event in
the progression from steatosis to steatohepatitis, as Tregs
may help control hepatic inflammation [33].
T helper type 17 cells (TH17 cells) are another subset of
T cells that produce interleukin-17 (IL-17) and mediate
various immune responses. TH17 cells play a role in
mediating pathogen clearance and in inflammatory
responses in tissues. Studies have shown the importance of
TH17 cells in autoimmune liver diseases, chronic viral
hepatitis, alcoholic liver disease, and hepatocellular carci-
noma [34–36]. Tang et al. [37] show that there are
increased numbers of TH17 cells in the liver after an
8-week HFD feeding and that these cells are associated
with the progression of hepatic steatosis and inflammation
through the production of IL-17. The same group suggests
that the balance between TH17 cells and Tregs could play a
role in the progression of NASH; however, further studies
need to be done to answer this question.
Pathogen-associated molecular patterns (PAMPs)
PAMPs are exogenous danger signals derived from
microbes that result in inflammation. PAMPs are known to
contribute to inflammation in NASH by signaling through
PRRs, leading to the activation of both the innate and
adaptive arms of the immune system (Fig. 1). PAMPs are
recognized by a diverse array of pattern recognition
receptors (PRRs), including Toll-like receptors (TLRs),
nucleotide-binding and oligomerization domain (NOD)-
like receptors (NLRs), RIG-I like receptors (RLRs), and
other non-specific sensors, e.g., C-type lectin receptors
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(CLRs) [38, 39] (Fig. 2). PAMPs are expressed by bacteria,
viruses, parasites, and fungi, and they include lipids, lipo-
proteins, nucleic acids, and proteins [40].
Toll-like receptors (TLRs)
There are 10 and 13 known TLRs in humans and mice,
respectively. In the liver, TLRs are expressed on KCs,
hepatocytes, SECs, and HSCs. TLRs recognize a wide
variety of PAMPs and are found in different cellular
locations: TLRs 2, 4, 5, 6, and 11 are found on extracellular
surfaces, whereas TLRs 3, 7, 8, and 9 are expressed
exclusively in intracellular vesicles, such as endosomes,
lysosomes, and the endoplasmic reticulum [39]. Once a
molecular pattern has been recognized by the TLR,
downstream signaling is initiated, resulting in inflamma-
tory and antiviral responses. Each TLR is associated with a
different set of adaptor proteins. For example, the adaptor
myeloid differentiation factor 88 (MyD88) is shared by all
TLRs, except TLR3, and leads to recruitment of the IL-1
receptor (IL-1R)-associated kinase family. TLR signaling
results in the activation of transcription factors nuclear
factor kappa B (NF-jB), activator protein-1 (AP-1), or
interferon regulatory factors, leading to the transcription of
inflammatory cytokines, chemokines, or type I interferons,
respectively.
TLR2/TLR1/TLR6
TLR2 recognizes a variety of PAMPs from bacteria, fungi,
parasites, and viruses. These include bacterial lipoprotein,
peptidoglycan, and lipoteichoic acid [41]. Dimerization of
TLR2 with TLR1 or TLR6 provides additional specificity
in ligand recognition. TLR2 deficiency has been shown to
accelerate MCD diet-induced steatohepatitis and fibrosis
[42, 43]. However, another group found that TLR2-defi-
cient mice fed a choline-deficient amino acid (CDAA) diet
had similar steatosis to wild-type mice, but decreased
inflammatory cell infiltration and hepatocyte ballooning,
suggesting that while steatosis is independent of TLR2
signaling, TLR2 appears to play a role in inflammation
[44]. The same group showed that a TLR2 ligand activates
Fig. 1 Immune response in NASH. The immune response in NASH
is initiated by both pathogen-associated molecular danger signals and
danger-associated molecular signals. This response involves both the
innate and adaptive branches of the immune system and results in
inflammation
Fig. 2 Pattern recognition
receptors in NASH. A variety of
pattern-associated molecular
patterns and danger-associated
molecular patterns are involved
in the pathogenesis of NASH.
PAMP and DAMP signaling can
occur through various PRRs,
including Toll-like receptors,
nucleotide-binding and
oligomerization domain (NOD)-
like receptors, and RIG-I like
receptors. PRR signaling can
result in steatosis, insulin
resistance, and inflammatory
cell activation and recruitment
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both KCs and HSCs in vitro, but in vivo it was determined
that KCs were responsible for TLR2-mediated liver
inflammation and fibrosis. TLR2 knockout mice fed a HFD
showed improvement in glucose tolerance and a decrease
in steatosis [45]. The differences seen between the various
studies could be secondary to different diets that induce
steatohepatitis, as the CDAA and HFD diet result in weight
gain and insulin resistance, which is not seen in the MCD
diet. Another possibility is differences in intestinal micro-
flora between the mice that could be a source of TLR2
ligands.
TLR3
TLR3 is present exclusively in intracellular vesicles, such
as endosomes and lysosomes, and it recognizes double-
stranded RNA (dsRNA) and poly(I:C), a synthetic analog
of dsRNA, along with genomic RNA of a variety of other
viruses [40]. Activation of TLR3 results in type I interferon
and inflammatory cytokine production and thus produces
an antiviral immune response. TLR3 activation has been
implicated in a number of autoimmune diseases, including
type I diabetes mellitus and Hashimoto’s thyroiditis [46,
47]. In NAFLD, Wu et al. [48] showed that TLR3 knockout
mice fed a HFD displayed an improvement in glucose
tolerance and an improvement in lipid and cholesterol
metabolism, with no protection from HFD-induced obesity.
It is yet to be established what the ligand leading to TLR3
activation is in NAFLD.
TLR4
TLR4 is the most widely studied TLR, and it recognizes a
diverse array of PAMPs that include LPS, Pseudomonas
exoenzyme, taxol, and other components of microbes [41].
TLR4 signaling occurs in a slightly different manner than
in the other TLRs, as it requires an accessory molecule,
glycoprotein MD2, to effectively bind LPS. Signaling is
initiated through two different pathways, the MyD88-
dependent pathway and the MyD88-independent pathway,
which involves TIR-domain-containing adaptor-inducing
interferon-b (TRIF) and the TRIF-related adaptor protein
[39].
There have been numerous studies elucidating the role
of TLR4 in NASH. Increased serum LPS levels are
detected in patients with NASH and in animal models of
NASH [49, 50], suggesting increased TLR4 activation.
Furthermore, fructose, which is abundant in the Western
diet, results in increased hepatic steatosis and inflammation
potentially by causing increased intestinal bacterial over-
growth and intestinal permeability resulting in increased
TLR4 signaling [51]. In MCD and HFD-induced steato-
hepatitis and fibrosis, TLR4 deficiency attenuates
steatohepatitis [9, 52, 53]. In the MCD model, there is
increased susceptibility to LPS stimulation, further impli-
cating the TLR4 pathway in being involved in the patho-
genesis of NASH [42]. MD2 knockouts also display a
partial protection from MCD diet-induced steatohepatitis
[52]. Both TLR4 and MD2 knockout mice display reduced
NADPH oxidase activation and lipid peroxidation com-
pared to WT mice, suggesting reduced free radical levels
and improved lipid content. Furthermore, it has been sug-
gested that TLR4 activation and sensitization of HSCs may
be the link between inflammation and fibrosis in NAFLD
and other forms of chronic liver disease, as HSCs are
involved in the regulation of the extracellular matrix and
tissue remodeling [54].
TLR9
TLR9 is expressed in intracellular vesicles and recognizes
bacterial/viral DNA and CpG DNA. TLR9 ligands directly
activate DCs, macrophages, and B cells, and they result in
a strong T helper 1 (TH1) response. In murine NASH
models, there are elevations in bacterial DNA in the
plasma, which is a ligand for TLR9 [44]. The same group
showed that TLR9 deficiency attenuates CDAA diet-
induced steatohepatitis and fibrosis, suggesting a critical
role of TLR9 in NASH [44].
NOD-like receptors
The NLRs are a family of intracellular pattern-recognition
receptors that are involved in the innate immune response
to microbes by recognizing PAMPs (Fig. 2). NLRs also
play an important role in recognizing host-derived signals,
known as DAMPs. The NLR family is characterized by the
presence of a central nucleotide-binding and oligomeriza-
tion domain, flanked by C-terminal leucine-rich repeats and
N-terminal caspase recruitment or pyrin domains. Further
details of NLR complexes and their molecular structure are
described elsewhere [55]. To date, four NLR prototypes
have been identified, NLRP1 (NALP1), NLRP3 (NALP3,
cryoporin), NLRC4 (IPAF), and AIM2 [56].
NLRs are part of intracellular multi-protein complexes
known as inflammasomes that are assembled and activated
following cellular infection or stress and result in inflam-
mation. Inflammasome activation is thought to involve two
steps, in which the first signal upregulates inflammasome
expression and is generally from TLR activation, and the
second step involves a ligand triggering inflammasome
activation [56]. Inflammasome activation occurs in innate
immune cells, including macrophages, neutrophils, and
DCs, as well as non-immune cells, including hepatocytes,
HSCs, endothelial cells, and myofibroblasts [57]. Further-
more, inflammasome activation results in the production of
S774 Hepatol Int (2013) 7 (Suppl 2):S771–S781
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proinflammatory cytokines, including IL-1b and interleu-
kin-18 (IL-18) [55]. The importance of the contribution of
each cell type has not been entirely elucidated; however,
one study showed that IL-1b or IL-1a depletion in hepa-
tocytes, but not bone marrow cells, resulted in protection
from diet-induced steatohepatitis [58].
IL-1b signaling plays an important role in NASH. IL-1R
knockout mice showed attenuated liver steatosis, injury,
and fibrosis following either a CDAA or HFD feeding [59].
In contrast, a different group found that both IL-1R
knockout mice and WT mice treated with IL-1R antagonist
(IL-1Ra) that received an MCD diet showed decreased
liver steatosis but no improvement in inflammation or
fibrosis (Csak et al., unpublished data). IL-1Ra-deficient
mice showed severe hepatic steatosis and fibrosis on an
atherogenic diet compared to WT mice fed the same diet
[60]. Similarly to the IL-1R knockout mice, IL-1b knock-
out mice displayed attenuated hepatocellular damage, ste-
atosis, and fibrosis following an atherogenic diet feeding
[58]. The same group found that IL-1a knockout mice also
displayed attenuated liver damage and fibrosis after an
HFD feeding.
Thus far, mainly NALP3 has been found to have a
potential role in the development of NASH. Further studies
need to be completed with the other NLRs to determine
whether they have a role in NASH.
NALP3
The NALP3 inflammasome is the most widely studied in-
flammasome and consists of the NLRP3 scaffold, the
apoptosis-associated speck-like protein containing a cas-
pase recruitment domain (ASC) adaptor, and the effector
molecule, a proinflammatory protease, pro-caspase-1.
NALP3 is involved in antibacterial, viral, fungal, and
parasitic immune responses [61]. Components of the NALP3
inflammasome and resultant caspase-1 activation are seen in
the livers of mice fed both a HFD and a MCD diet [52, 62].
Increased expression of NALP3 and caspase-1 is also seen in
the liver of humans with NASH [52], and the levels of
expression in adipose tissue are directly correlated with the
extent of type 2 diabetes mellitus in obese individuals [62].
Inflammasome upregulation has been found to occur in
innate immune cells [56] as well as in primary hepatocytes of
MCD diet-fed mice [52], suggesting that there are multiple
cell types in the liver that undergo inflammasome activation
and contribute to inflammation.
Mice lacking NALP3, ASC, or caspase-1 have been
shown to display a decrease in weight gain and fat mass, and
improved insulin resistance following a HFD feeding.
However, there were differences among the three knockouts,
with ASC knockout mice displaying decreased hepatic ste-
atosis and liver triglyceride levels, whereas NALP3 and
caspase-1 knockout mice did not show this change [63]. In
contrast, a different group showed that ASC knockout mice
are prone to steatosis, obesity, and increased glucose resis-
tance [64]. This group suggested that the difference they find
is due to alterations in the intestinal microbiome.
NLRP6 and NLRP12
NLRP6 and NLRP12 have mainly been studied in the
context of colonic microbiota and inflammation [61].
NLRP6 knockout mice co-housed with WT mice display
increased hepatic inflammation. On the other hand,
NLRP12 mice co-housed with WT mice did not display
any change in hepatic pathology. The group concludes that
a transmissible colonic microbiota present in inflamma-
some-deficient mice results in NASH in the co-housed WT
mice [64].
RLRs and viral infections
Patients with NASH have been shown to have accelerated
progression of liver disease and fibrosis and decreased
efficacy of treatment with antiviral therapy in the setting of
co-infection with hepatitis C virus (HCV) and human
immunodeficiency virus [65, 66].
The mechanism behind the increased susceptibility to
HCV infection in the setting of NASH has been attributed to
a defect in the TLR3 signaling pathway. HCV is recognized
in its dsRNA form by TLR3 and the RLRs, which include
helicase receptors retinoic acid-inducible gene I (RIG-I) and
melanoma differentiation-associated gene 5. RLRs are
molecules that sense viral RNA molecules, resulting in the
triggering of a danger signal. The adaptor mitochondrial
antiviral signaling protein (MAVS) associates with the outer
mitochondrial membrane and is crucial for inflammatory
cytokine and interferon production after dsRNA binding to
the helicases [67]. Whether endogenous RNA triggers RLR
activation in NASH has yet to be studied.
Our group has shown that in the setting of MCD diet-
induced steatohepatitis, mice challenged with the synthetic
dsRNA, poly(I:C) show an inability to mount an efficient
anti-viral response as demonstrated by impaired type I IFN
production [16]. This deficiency was found to be secondary
to dissociation of MAVS from the mitochondria to the
cytosol and necrosis. Despite a decrease in inflammatory
cytokine production, there was still an increase in liver
damage in mice with MCD-diet-induced steatohepatitis.
Microbiome
Recently, the role of the intestinal microbiota and probio-
tics in liver diseases has been a popular area [64, 68]. It is
well known that patients with NAFLD have increased
Hepatol Int (2013) 7 (Suppl 2):S771–S781 S775
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intestinal permeability and a higher incidence of bacterial
overgrowth in the small intestine compared to patients with
normal livers [49]. The translocation of bacterial compo-
nents promotes hepatic inflammation through TLR signal-
ing and KC activation [9] (Fig. 3). An increase in TLR
agonists in the intestine has been shown to drive the pro-
gression of NASH in WT mice [64].
In mice lacking various inflammasome components, a
significant expansion of the intestinal bacteria Porphy-
romonadacae was detected following a HFD and MCD diet
feeding. These bacteria have been implicated in the
development and progression of metabolic syndrome in
both mice and humans. Treatment with antibiotics abol-
ished the bacteria [64, 69]. Rats fed a HFD and treated with
probiotics displayed a change in intestinal microflora and a
reduced level of hepatic cholesterol and triglycerides [70].
Treatment with the probiotic VSL no. 3 in mice fed an
MCD diet resulted in attenuation of fibrosis without pro-
tecting from inflammation or steatosis [71].
Danger-associated molecular patterns
DAMPs are endogenous molecules released from damaged
cells that trigger sterile inflammation [72]. Sterile inflam-
mation is a response that occurs in all tissues in response to
injury and cellular damage. In NASH there is a chronic
state of sterile inflammation resulting from the presence of
DAMPs. Similarly to PAMPS, DAMPs activate both the
innate and adaptive branches of the immune response
(Fig. 1). A wide variety of DAMPs have thus far been
identified in many different diseases and are reviewed
elsewhere [73]. DAMPs activate PRRs, of which the best
characterized are TLRs (Fig. 2). In NASH, it has been a
challenge to show an increase in the levels of serum
DAMPs, and further research is needed to elucidate whe-
ther DAMPs that play a role in other diseases also con-
tribute to the pathogenesis of NASH [73]. Some of the
DAMPs that have been identified, such as high-mobility
group-1 (HMGB1) and FFAs, signal through several TLRs
and, in the case of FFAs, a NLR.
Toll-like receptors (TLRs)
TLR2
It has not yet been determined whether there are DAMPs
that directly activate the TLR2 ligand in NASH. Stimula-
tion of TLR2 in KCs with a TLR2 ligand in the presence of
the FFA palmitic acid (PA) results in inflammasome acti-
vation and increased IL-1b production, suggesting a cross-
talk between PAMPs and DAMPs [44]. It has been
hypothesized that HMGB1 may also activate TLR2 in
addition to TLR4. As discussed earlier, there are opposing
phenotypes published by different groups in the setting of
TLR2 knockout mice in a diet-induced steatohepatitis
model, suggesting that differences in intestinal microflora
could be responsible for TLR2 ligand production [44].
TLR4
A variety of DAMPs have been described that activate
TLR4, including HMGB1, hyaluronic acid, heat shock
proteins, defensins, and fibrinogen [41]. The role, if any, of
most of these DAMPs has not yet been conclusively
determined in NASH.
HMGB1 is a highly conserved nuclear protein that
facilitates regulatory protein binding to DNA [74]. It is
constitutively expressed by most cells and is released upon
cell injury or death. Yanai et al. [75] describe HMGB
proteins as acting as universal intracellular sensors of
cytosolic nucleic acids. For example, HMGB1 is released
from necrotic cells leading to KC and monocyte stimula-
tion by acting as an endogenous TLR4 ligand either alone
or with other molecules, such as endotoxin or ssDNA [76].
Furthermore, increased hepatocyte expression and release
of HMGB1 triggers TLR4 and MyD88 signaling and
inflammation in response to FFA infusion or HFD [53].
The interaction between HMGB1 and FFAs in TLR4 sig-
naling in NASH is yet to be studied in depth. It has not yet
been determined whether HMGB1 directly binds to TLR4
or forms complexes with other molecules.
Fig. 3 Cross-talk in NASH. The immune and inflammatory response
in NASH involves an interaction among the liver, gut, and adipose
tissue. Various adipokines, including adiponectin, interleukin-6 (IL-
6), leptin, tumor necrosis factor a (TNFa), and monocyte chemoat-
tractant protein-1 (MCP-1), are released by adipocytes and macro-
phages in adipose tissue and contribute to inflammation in the liver.
Increased gut permeability, bacterial overgrowth, and changes in
microbiota can result in the production of LPS, fatty acids, and other
factors that contribute to liver inflammation and steatosis
S776 Hepatol Int (2013) 7 (Suppl 2):S771–S781
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FFAs have also been described to contribute to the
pathogenesis of NASH [1, 77]. FFA levels have been
reported to be elevated in mice with HFD-induced, MCD
diet-induced, or leptin-deficiency diet-induced steatohepa-
titis [78–80]. Saturated FFAs result in the activation of the
TLR4 pathway in adipocytes and macrophages resulting in
inflammation through an unclear mechanism [73]. How-
ever, it does not appear that FFAs are ligands for TLR4 in
either KCs or HSCs [44, 81].
TLR5
Although not expressed in mammalian livers, TLR5
knockout mice have altered gut flora. These mice develop
obesity, steatosis, and insulin resistance secondary to
hyperphagia. Transmission of the gut flora from these mice
to WT mice resulted in transmission of the disease phe-
notype [82].
TLR9
Bacterial DNA is often detected in the blood of both rodents
and humans with chronic liver diseases [83, 84]. DNA from
dying hepatocytes in NASH can act as an endogenous ligand
for TLR9 [85]. The DNA from apoptotic cells is modified by
caspase-activated DNAse-mediated cleavage and methyla-
tion and oxidative damage, resulting in the ability to activate
TLR9 [85]. The combination of both exogenous and
endogenous bacterial DNA could potentially lead to an
exponential increase in TLR9 activation in NASH. Mito-
chondrial dysfunction has also been implicated in the path-
ogenesis of NASH, resulting in increased oxidative stress,
cytokine production, and cell death [86]. Mitochondrial
DNA, which resembles bacterial DNA in having non-
methylated CpG motifs, released by injured cells results in
the activation of neutrophils through TLR9 signaling. Fur-
thermore, HMGB1 has also been described to interact with
TLR9, likely involved in the signal response to CpG DNA
[75], but its role in NASH is not yet clear.
NOD-like receptors (NLRs)
NALP3
The NALP3 inflammasome can be activated by a variety of
host-derived molecules. These activators include extracel-
lular ATP, hyaluronic acid, amyloid-b, and uric acid
crystals [55].
Both experimental and clinical studies have shown a
link between IL-1b and IL-18, which are produced by in-
flammasome activation, to the development of metabolic
syndrome [87, 88]. The underlying mechanism has not yet
been elucidated.
Obesity has been shown to result in adipocyte hyper-
trophy and preferential M1 macrophage infiltration [89].
The NALP3 inflammasome is activated in these macro-
phages by the saturated fatty acids PA and lipotoxic
ceramics [62, 90]. Hepatocytes treated with PA displayed
upregulation of the NALP3 inflammasome and caspase-1
activation. Hepatocytes stimulated with PA have been
shown to activate liver mononuclear cells, suggesting that
hepatocytes can transfer inflammasome activation to sur-
rounding immune cells [52]. Furthermore, pre-treatment of
hepatocytes with PA resulted in sensitization to stimulation
with LPS and a significantly higher level of caspase-1 than
treatment with either PA or LPS alone [52]. In addition to
leading to inflammation, fatty acids also induce apoptosis
and the subsequent release of DAMPs. The release of
mitochondrial DNA into the cytosol in response to LPS and
ATP stimulation is dependent on NALP3 and is necessary
to achieve robust caspase-1 activation and IL-1b produc-
tion [91]. Mitochondrial DNA appears to also act by
directly binding to and activating NALP3 [92] and likely
contributes to the pathogenesis of NASH.
Role of adipose tissue
Adipose tissue is a highly active tissue that has both endo-
crine and immune functions, and has been found to have a
role in mediating disease. In obesity, there is dysfunctional
adipose tissue resulting from hypertrophic adipocytes and
macrophage infiltration into adipose tissue [93]. The liver is
an important target for adipose tissue, and its dysregulation
in obesity can contribute to steatohepatitis (Fig. 3). The
increase in FFAs seen in obesity results in TLR4 activation
in adipocytes and macrophages, resulting in inflammation.
Furthermore, there is an increase in circulating FFAs sec-
ondary to an increase in adipose FFAs, resulting in an
increase in portal FFAs, thus contributing to NAFLD and
eventually NASH [94]. Activation of adipose tissue mac-
rophages also results in ectopic fat deposition in the liver.
Hypertrophic adipocytes behave similarly to macro-
phages and produce adipokines similarly to foam cell fat-
loaded macrophages in arterial plaques [6]. The production
of insulin-sensitizing adipokines is reduced, such as
adiponectin, resulting in decreased insulin sensitivity.
Overexpression of adiponectin in genetically obese leptin-
deficient ob/ob mice results in a reversal of the diabetic
phenotype and reduced liver fat content, despite retaining
the obese phenotype, suggesting that adiponectin plays a
critical role in preventing both local and systemic inflam-
mation [95].
Other adipokines that have a proinflammatory role are
the cytokines interleukin-6 (IL-6) and TNFa as well as the
chemokine monocyte chemoattractant protein-1 (MCP-1).
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IL-6 levels are elevated in the serum and adipocytes of
obese patients, and the level of expression is significantly
higher in adipose tissue than in liver, suggesting that adi-
pose tissue is the main source of IL-6 in NASH [96, 97].
Furthermore, TNFa expression is profoundly increased in
adipose tissue of obese patients [96]. Adipose tissue-
derived IL-6 and TNFa likely target the liver, as exposure
to both of these cytokines has an effect on hepatic insulin
resistance [98]. IL-6-deficient mice fed a MCD diet or HFD
develop worsening inflammation and liver damage [99,
100]. However, blockade of IL-6 signaling by a neutral-
izing antibody against the IL-6 receptor resulted in
enhanced liver steatosis and improved liver injury in MCD-
fed mice [101]. The balance in the levels of IL-6 appears to
play an important role in the development of liver injury.
Conclusions
NAFLD is a disease that encompasses a wide range of
pathology, from steatosis to steatosis with inflammation to
fibrosis; it is commonly seen in the presence of the meta-
bolic syndrome. It is clear that there are complex immune
and inflammatory pathways that result in the progression of
NASH, involving signaling in various cell types that are
stimulated by PAMPs and DAMPs as well as interaction
between different cell types and tissues. While there has
been a significant amount of research examining the
immune and inflammatory pathways in NAFLD, many
questions remain. The reason why certain people develop
steatohepatitis and progress to cirrhosis while others only
develop steatosis has not yet been determined. There are
likely undiscovered PAMPs and DAMPs that contribute to
NAFLD, as well as unknown interactions between various
PAMPs and DAMPs. Furthermore, understanding cell
specificity in both NLR and TLR activation in NASH is an
area that deserves further investigation and could be
important as a target for future therapeutics. In addition,
more studies looking at the interactions of the components
of the adaptive immune system are warranted.
Despite the significant advancement in knowledge about
the development of NAFLD, a dearth of effective treat-
ments remains, aside from weight loss and treating asso-
ciated conditions, such as hyperlipidemia and diabetes.
Continuing to elucidate the mechanisms and pathogenesis
behind the progression of NAFLD is critical to being able
to design therapeutic interventions that can directly target
the liver.
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